Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

35 results about "LYMPHOCYTE SEPARATION MEDIUM" patented technology

A lymphocyte separation medium is a device used to isolate lymphocytes from whole blood.

Preparation method and preservation method of clinical application-level placental hematopoietic stem cells

The invention provides a preparation method of clinical application-level placental hematopoietic stem cells. The preparation method comprises the steps of pretreating a fresh delivered placenta immediately and then separating out umbilical arteries and umbilical veins, pouring a cleaning fluid into the chorionic vessels of the placenta and colleting the cleaning fluid after pouring, pouring an enzyme digestion fluid into the chorionic vessels of the placenta and digesting at 37 DEG C for 5-20min, pouring the collected fluid into the placenta and collecting the liquid after pouring, centrifuging the obtained fluid and re-suspending cells after removing the supernatant, and separating the resuspended cell suspension through a two-step process with hydroxyethyl starch and a lymphocyte separation medium to obtain the clinical application-level placental hematopoietic stem cells. The method is capable of increasing the number and the activity of the prepared placental hematopoietic stem cells and the content of CD34 positive cells, and the prepared placental hematopoietic stem cells are at the clinical application level and free of potential pathogenic contamination, and moreover, the method is low in preparation cost.
Owner:台州恩源生物科技有限公司

Method for sequential culture of human umbilical cord blood mesenchymal stem cells by using two culture media

The invention discloses a method for sequential culture of human umbilical cord blood mesenchymal stem cells by using two culture media. A lymphocyte separation medium density gradient centrifugation method is used for separating umbilical cord blood mononuclear cells, a dulbecco modified eagle medium (DMEM)/F12 is used for primary culture of the mesenchymal stem cells of the human umbilical cord blood, and the method increases adherence of the cells, reduces growth of osteoclast like cells remarkably, facilitates formation of human umbilical cord blood-mesenchymal stem cells (hUCB-MSCs) colonies, and greatly improves successful rate of culture of the hUCB-MSCs. The DMEM/F12 is used continuously for subculturing to a P2 generation, the method is combined by a using enzymatic digestion and differential velocity adherent method simultaneously, and the method facilitates purification of P1-P2 generation cells remarkably. A P3 generation and the following generations are cultured by using an Oricell human umbilical cord mesenchymal stem cell culture medium, marker proteins and good morphological characteristics and growth characteristics of the hUCB-MSCs are maintained, and multilineage differentiation potential of the hUCB-MSCs is maintained. In addition, costs of the culture media adopted by the method are reduced remarkably.
Owner:AFFILIATED HOSPITAL OF ZUNYI MEDICAL COLLEGE

Placental hematopoietic stem cell and preparation method thereof and placental hematopoietic stem cell injection

The invention relates to the field of biology and discloses a placental hematopoietic stem cell and a preparation method thereof and a placental hematopoietic stem cell injection. The preparation method comprises the following steps of: after pretreating a placenta, digesting the treated placenta by using collagenase type IV digestive juice and collagenase type II digestive juice, then washing and filtering and respectively collecting first filtrate and first residue; digesting the first filter residue by using collagenase type I digestive juice and the collagenase type II digestive juice in the first step and then washing, filtering and collecting second filtrate; combining the filtrate from two times, centrifuging and discarding supernate, re-suspending and precipitating; adding a resuspension solution into a lymphocytes separation medium; and carrying out density gradient centrifugation, collecting a buffy coat cell solution on an intermediate layer and centrifuging and discarding supernate to obtain the placental hematopoietic stem cell. According to the placental hematopoietic stem cell and the preparation method thereof disclosed by the invention, collagenase type IV and collagenase type II are combined, collagenase type I and collagenase type II are combined and the hematopoietic stem cell is prepared by fully digesting the placenta according to the characteristics of different collagenases, so that the quantity and the vitality of the prepared hematopoietic stem cell are improved.
Owner:BOYALIFE

Breast cancer targeted Car-NK cell preparation method

The invention discloses a method for preparing Car-NK cells for breast cancer. The method comprises the following steps: collecting peripheral enriched blood from a patient, filtering out leukocytes, slowly moving it into a centrifuge tube containing lymphocyte separation liquid, and using a density gradient Centrifuge, absorb the buffy coat, and obtain peripheral blood mononuclear cells; take 90 mL of the resuspension, add inactivated autologous serum 10 mL and IL-2 10 ng/mL, inoculate into six-well culture plates, and in six-well culture plates Add 0.9% sodium chloride injection and Lymactin-NK; after culturing for 36-48h, add IL-2, IL-15 and IL-21 to the culture plate at a final concentration; transfect and amplify NK cells with lentivirus cultured to obtain CAR-NK cells. The invention discloses a preparation method of Car-NK cells, which comprises separating nuclear cells from peripheral blood of breast cancer patients by Ficoll method, and amplifying NK cells in vitro through IL-2+IL-15+IL-21 combined culture scheme, The preparation method is convenient and easy to operate, and the obtained Car-NK cells can be injected into the patient's body through the method of preparing cell preparations, which is of great help to the treatment of breast cancer.
Owner:ANHUI HUIEN BIOTECH

Method for preparing soluble human recombinant MICA protein

The invention discloses a method for preparing a soluble human recombinant MICA protein, which comprises the following steps of: a step 1 of sampling 30ml of in-vitro peripheral venous blood donated by a healthy adult volunteer, diluting the in-vitro peripheral venous blood by physiological saline and separating out an offwhite lymphocyte layer by a lymphocytes separation medium; a step 2 of extracting an RNA (Ribose Nucleic Acid) of processed offwhite lymphocytes by a TRIZOL, carrying out sequence screening on the RNA, planting the RNA into a rhabdovirus genome, carrying out recombination, collection, dialysis and centrifugation to obtain an MICA protein and filtering the MICA protein by a CENTRICON ultrafilter; a step 3 of purifying a target protein; and a step 4 of identifying the MICA target protein. The soluble human recombinant MICA protein prepared by the preparation method is the MICA protein of which a molecular structure domain is closer to the natural state and has the advantages of convenience, rapidness, sensitivity, good repetitiveness and the like. Due to successful application of the soluble human recombinant MICA protein in an in-vitro immunological rejection model, practical support is provided and a solid foundation is laid for in-vivo experiments and clinical application of animals.
Owner:ZHEJIANG UNIV

Method for sequential culture of human umbilical cord blood mesenchymal stem cells by using two culture media

The invention discloses a method for sequential culture of human umbilical cord blood mesenchymal stem cells by using two culture media. A lymphocyte separation medium density gradient centrifugation method is used for separating umbilical cord blood mononuclear cells, a dulbecco modified eagle medium (DMEM) / F12 is used for primary culture of the mesenchymal stem cells of the human umbilical cord blood, and the method increases adherence of the cells, reduces growth of osteoclast like cells remarkably, facilitates formation of human umbilical cord blood-mesenchymal stem cells (hUCB-MSCs) colonies, and greatly improves successful rate of culture of the hUCB-MSCs. The DMEM / F12 is used continuously for subculturing to a P2 generation, the method is combined by a using enzymatic digestion and differential velocity adherent method simultaneously, and the method facilitates purification of P1-P2 generation cells remarkably. A P3 generation and the following generations are cultured by using an Oricell human umbilical cord mesenchymal stem cell culture medium, marker proteins and good morphological characteristics and growth characteristics of the hUCB-MSCs are maintained, and multilineage differentiation potential of the hUCB-MSCs is maintained. In addition, costs of the culture media adopted by the method are reduced remarkably.
Owner:AFFILIATED HOSPITAL OF ZUNYI MEDICAL COLLEGE

Lymphocyte separating medium and preparation method thereof

The invention discloses a lymphocyte separating medium and a preparation method thereof, the lymphocyte separating medium is characterized by comprising the following components: glycerin, ethanol, sucrose, meglumine, diatrizoic acid and epichlorohydrin; the sucrose and the diatrizoic acid are added into an ethanol solution to synthesize a water-soluble polysucrose ethanol solution as a molecular sieve separating medium; the method also includes adding meglumine and epichlorohydrin into glycerol, preparing a clear biological solution at room temperature, putting the biological solution into a dialysis paper bag, putting the dialysis paper bag into deionized water, carrying out ion replacement culture for a period of time, and detecting that the dialysis paper bag does not contain redundant foreign ions; then adjusting the pH value of the two solutions to a proper range by using sodium hydroxide and hydrochloric acid; finally, mixing and stirring the two solutions with the pH value adjusted to be stable to be uniform, and obtaining the lymph separation medium. The lymphocyte separation efficiency is high, the separation purity is high, the quality of lymphocytes is improved, high-quality lymphocytes can be obtained, and the lymphocyte separation medium is suitable for clinical application and popularization.
Owner:无锡华精生物科技有限公司

ADSCs and EPCs stem cell system capable of promoting recovery of microcirculation blood supply of graft

The invention discloses an ADSCs and EPCs stem cell system capable of promoting recovery of microcirculation blood supply of a graft. The ADSCs and EPCs stem cell system capable of promoting recoveryof microcirculation blood supply of the graft is composed of adipose-derived stem cells (ADSCs) derived from adipose tissue and endothelial progenitor cells (EPCs) derived from peripheral blood. The ADSCs are extracted by adopting an enzymolysis method for culture; and the peripheral blood is collected, after heparin is used for anticoagulation and methylcellulose is used for sedimentation of redblood cells, gradient centrifugation is conducted by adopting a lymphocyte separation medium, and the EPCs are collected and purified by adopting an adherence method. The ADSCs and the EPCs which arecultured separately are subjected to co-culture according to a cell ratio of the ADSCs to the EPCs of 1:1 and a total cell concentration of 20000/cm<2>. According to the ADSCs and EPCs stem cell system capable of promoting recovery of microcirculation blood supply of the graft, nutrition supply of the graft is improved, transplanted adipose tissue survival and adipose cell differentiation are promoted, the transplantation efficiency is improved, and a treatment cycle is shortened. On the other hand, all the cells are extracted from the body of a patient, injury is minor, and pain is little, sothat the ADSCs and EPCs stem cell system capable of promoting recovery of microcirculation blood supply of the graft is liable to be accepted by the patient.
Owner:KUNMING MEDICAL UNIVERSITY

Isolation and cultivation method of prokaryotic cells of human umbilical cord blood mesenchyme stem cells

The invention provides an isolation and cultivation method of prokaryotic cells of human umbilical cord blood mesenchyme stem cells, which is applied to a dimethyl sulfoxide induction process which enables the human umbilical cord blood mesenchyme stem cells to be differentiated into neuronal cells. The induction process uses serum-free dulbecco modified eagle medium (DMEM) containing dimethyl sulfoxide and butylated hydroxyanisole to induce the human umbilical cord blood mesenchyme stem cells to be differentiated into the neuronal cells. The isolation and cultivation method includes: collecting umbilical cord blood of a normal full-term cesarean section fetus under an aseptic condition, anti-freezing through heparin, separating single prokaryotic cell of the umbilical cord blood by using lymphocyte separation medium, cultivating and purifying by using partial acidic culture medium to obtain anchorage-dependent cells, obtaining application dimethyl sulfoxide which is amplified by a third generation to induce the mesenchymal stem cells (MSCs) to be differentiated towards the neuronal cells, and marking and displaying the induced MSCs in immunohistochemical mode to express a neurofilament protein (NF) and neuron specific endase (NSE). The human umbilical cord blood MSCs can be cultivated and amplified in vitro, can be differentiated towards neuron-like cells by using induction of the dimethyl sulfoxide, and provides a novel cell source for wound repair of central nervous systems.
Owner:江苏迈健生物科技发展股份有限公司

Method for extracting high-quality B cells from bone marrow, peripheral blood and lymphoma tissue

The invention discloses a method for extracting high-quality B cells from bone marrow, peripheral blood and lymphoma tissue, which comprises the steps of respectively taking the peripheral blood and the bone marrow of a lymphoma patient, adding hydroxyethyl starch, standing and taking supernatant; taking a lymphocyte separation medium with the same volume as the supernatant, adding the supernatant into the lymphocyte separation medium, and centrifuging; taking the centrifuged white film layer, washing and resuspending; splitting tumor tissue of the lymphoma patient, cutting the tissue and incubating; transferring the supernatant into PBS containing 10% of serum, and repeatedly washing the tissue; and enabling the obtained supernatant to pass through a cell sieve, centrifuging, collecting cell precipitate, washing and resuspending. By changing the experimental method for separating and purifying the bone marrow and the peripheral blood, the B cells from the bone marrow and the peripheral blood are extracted more efficiently, and impurity cells are reduced; and by changing a lysis method of lymphoma tissues, more lymphoma cells are mildly and effectively extracted, and a necessary cell basis is provided for subsequent cell culture and single cell sequencing.
Owner:天津市环湖医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products